WO2022205645A1

WO2022205645A1 - Injectable dermal filler and preparation method therefor

Info

Publication number: WO2022205645A1
Application number: PCT/CN2021/103197
Authority: WO
Inventors: 王晓梅; 崔立国; 石旭东; 崔毅; 庄秀丽
Original assignee: 长春圣博玛生物材料有限公司
Priority date: 2021-04-02
Filing date: 2021-06-29
Publication date: 2022-10-06
Also published as: CN113230451A

Abstract

An injectable dermal filler, comprising the following raw materials: a polyester material, sodium hyaluronate, and a dispersant. The polyester material is selected from one or more of polycaprolactone, poly-L-lactic acid, poly-D-lactic acid, polyglycolic acid, and polyhydroxyalkanoate; the dispersant is mannitol and amino acid; and the amino acid is selected from one or more of glycine, alanine, valine, leucine, isoleucine, proline, serine, phenylalanine, tryptophan, and histidine. A preparation method for the dermal filler.

Description

A kind of injectable dermal filler and preparation method thereof

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is based on the Chinese patent application with the application number of 202110360171.5 and the application date of April 7, 2021, entitled "An injectable dermal filler and its preparation method", and claims the priority of the Chinese patent application. The entire contents of the Chinese patent application are incorporated herein by reference.

technical field

The present application relates to the technical field of medical cosmetology, in particular to an injectable dermal filler and a preparation method thereof.

Background technique

Injection of soft tissue fillers is a minimally invasive treatment for skin wrinkles and sag filling. Soft tissue fillers on the market mainly include cross-linked sodium hyaluronate gel, collagen, polylactic acid and calcium hydroxyapatite. Among them, the action time of cross-linked sodium hyaluronate gel and collagen in the skin is 6 to 12 months, and the action time of polylactic acid and calcium hydroxyapatite in the skin is about more than 2 years.

Polyester materials such as polylactic acid, polycaprolactone, etc., have the advantages of good biocompatibility, anticoagulation, non-toxicity and low immunity, so they are widely used in the fields of biomedicine and tissue engineering. Research in the past 30 years has shown that polyester materials and their monomers have good histocompatibility. Polyester materials can be hydrolyzed and degraded into low molecular weight fragments in a physiological environment, and low molecular weight fragments can be absorbed by macrophages. phagocytosis is degraded intracellularly. Among them, polylactic acid and polycaprolactone are used as the raw materials of dermal fillers, and many products containing polylactic acid and/or polycaprolactone have been used to fill skin wrinkles and depressions. Lactic acid microspheres and polycaprolactone microspheres, etc.

The existing conventional emulsification method adopts a relatively toxic emulsifier when preparing the microparticles, so it needs to be removed after post-treatment, and then the microparticles are obtained by drying and separation, and finally the microparticles and other dispersants or suspending agents are mixed and dispersed to obtain Dermal fillers, the preparation process is complicated.

SUMMARY OF THE INVENTION

In view of the problems existing in the prior art, the present application provides an injectable dermal filler and a preparation method thereof, which can simplify the preparation process of the dermal filler.

In a first aspect, the present application provides an injectable dermal filler, the dermal filler includes the following raw materials by mass percentage: polyester material, sodium hyaluronate, and dispersant.

Further, the polyester material is 20% to 80%, the sodium hyaluronate is 10% to 40%, and the dispersant is 10% to 60%; the skin filler is made of sodium hyaluronate and dispersant wrapped in polyester particles formed on the surface of similar materials.

Further, the dermal filler also includes water; 5% to 20% of polyester microparticles, 1% to 5% of sodium hyaluronate, 2% to 10% of dispersant and 65% to 90% of water; the skin The filler is a suspension of polyester microparticles in sodium hyaluronate and a dispersant.

The microparticles here may be spherical, irregular, rod-like, or the like.

Further, the dispersing agent is amino acid or mannitol.

Further, the dispersing agent is mannitol and amino acid; further, the mass percentage of the amino acid in the dermal filler is 2% to 50%. The mass percentage of the mannitol in the dermal filler is 2% to 50%.

Further, the polyester-based material is selected from one or more of polycaprolactone, poly-L-lactic acid, poly-D-lactic acid, polyglycolic acid and polyhydroxyalkanoate; further, the polyester-based material The intrinsic viscosity of the polyester material is 0.2-5.0 dL/g; further, the particle size of the polyester-based material is 0.01-200 μm.

Further, the amino acid is selected from one or more of glycine, alanine, valine, leucine, isoleucine, proline, serine, phenylalanine, tryptophan and histidine kind.

Further, the intrinsic viscosity of the sodium hyaluronate is 0.5 to 4.0 m ³ /kg.

The present application provides, in a second aspect, a method for preparing a dermal filler as described in the first aspect, the preparation method comprising the following steps: Step 1: dissolving sodium hyaluronate and a dispersant in water, and preparing a first mixture Step 2: Dissolve the polyester material in an organic solvent to prepare a second mixed solution; Step 3: Quickly add the second mixed solution to the first mixed solution, and fully emulsify to obtain a water-in-water solution oil emulsion; step 4: desolventizing the oil-in-water emulsion to obtain a suspension; step 5: lyophilizing the suspension to obtain polyester microparticles.

Further, the organic solvent is one of ethyl acetate, chloroform, toluene and dichloromethane; further, the organic solvent is dichloromethane or chloroform.

Further, in the step 3, the volume ratio of the first mixed solution and the second mixed solution is 1-20:1; further, in the step 4, the temperature of the desolvation is 20 ~50°C.

Compared with the prior art, the embodiments of the present application have at least the following beneficial effects:

1. In the examples of this application, by using sodium hyaluronate with better biocompatibility as the emulsifier of polyester microparticles, the process of removing the emulsifier is not required, and sodium hyaluronate will continue to be used as a suspending agent in the later stage of preparation, and the This can not only effectively repair skin cells, but also avoid the process of removing impurities caused by using polyvinyl alcohol and the like as emulsifiers for preparing microparticles in the prior art.

2. In the examples of this application, after mixing the solution of polyester material and the aqueous solution prepared by sodium hyaluronate and dispersant, the mixed solution is emulsified by ordinary stirring or emulsifier to form an oil-in-water emulsion, and then The emulsion is vacuum dried to remove the organic solvent and part of the water in the emulsion to obtain a suspension; the suspension can be used as a dermal filler. Compared with the existing technology for preparing microparticles by emulsification, the embodiments of the present application not only save the process of removing the emulsifier and drying the microparticles, but also save the process of redispersing the microparticles. Therefore, in the embodiments of the present application, the preparation of microparticles and the preparation of the dermal filler can be performed simultaneously, which simplifies the preparation process.

3. The dermal fillers prepared in the examples of the present application are not only suitable for deep dermis and subcutaneous tissue injection to fill deep wrinkles and depressions, but also suitable for superficial dermal water light injection to fill shallow wrinkles.

4. The dermal fillers of the embodiments of the present application can be used as long-acting water light needles.

Description of drawings

The accompanying drawings are used to provide further understanding of the embodiments of the present application, and constitute a part of the specification, and are used to explain the embodiments of the present application together with the following specific embodiments, but do not constitute limitations to the embodiments of the present application. In the attached image:

Fig. 1 is the scanning electron microscope picture of poly-L-lactic acid microparticles in the embodiment 1 of the present application;

Fig. 2 is the scanning electron microscope image of poly-L-lactic acid microparticles in the embodiment 2 of the application;

Fig. 3 is the scanning electron microscope picture of polycaprolactone microparticles in the embodiment 3 of the present application;

4 is a scanning electron microscope image of polylactic acid-polycaprolactone-polylactic acid particles in Example 4 of the present application;

5 is a scanning electron microscope image of poly-L-lactic acid-glycolic acid particles in Example 5 of the present application;

6 is a scanning electron microscope image of polycaprolactone microparticles in Example 6 of the present application.

Detailed ways

In order to make the objectives, technical solutions and advantages of the present application clearer, the technical solutions of the present application will be clearly and completely described below with reference to the embodiments of the present application. Obviously, the described embodiments are some, but not all, embodiments of the present application. Based on the embodiments in the present application, all other embodiments obtained by those of ordinary skill in the art without creative work shall fall within the protection scope of the present application.

The embodiments of the present application provide, in a first aspect, an injectable dermal filler, the dermal filler comprising the following raw materials by mass percentage: polyester material, sodium hyaluronate, and a dispersant.

In the examples of this application, sodium hyaluronate is used as the emulsifier and suspending agent for polyester microparticles. Since sodium hyaluronate is degradable and biocompatible, there is no need to remove sodium hyaluronate or add additional suspension. It avoids the residue of harmful substances caused by the use of other emulsifiers, thus omitting the process of removing impurities and particle redispersion compared with the prior art, and simplifying the preparation process of dermal fillers; because sodium hyaluronate can repair skin cells, Therefore, sodium hyaluronate can also be used as a functional raw material for dermal fillers, promoting the proliferation and differentiation of epidermal cells and scavenging oxygen free radicals, thereby preventing skin aging.

In a further embodiment, 20% to 80% of polyester material, 10% to 40% of sodium hyaluronate, and 10% to 60% of dispersant; the dermal filler is wrapped by sodium hyaluronate and dispersant Microparticles formed on the surface of polyester materials.

In a further embodiment, the dermal filler includes the following raw materials by mass percentage: 5% to 20% of polyester microparticles, 1% to 5% of sodium hyaluronate, 2% to 10% of dispersant and 65% of water. % to 90%; the skin filler is a suspension formed by polyester microparticles in sodium hyaluronate and a dispersant.

The dermal fillers of the embodiments of the present application are used in the state of suspension during clinical use. For example, when the dermal fillers are in the state of freeze-dried powder, the dermal filler of the freeze-dried powder is reconstituted to form a suspension for use. Or the suspension obtained after vacuum drying of the O/W emulsion in the preparation process is directly used for clinical use.

In a further embodiment, the dispersing agent is mannitol or amino acid; thus, by using mannitol or amino acid as the dispersing agent, not only can the polyester material in the second mixed solution be uniformly dispersed; but also It is degraded in the body, reducing the process of dispersing after dermal fillers.

In a further embodiment, the mass percentage of the mannitol in the dermal filler is 2% to 50%, and the mass percentage of the amino acid in the dermal filler is 2% to 50%. Thus, by using mannitol and amino acid as dispersants at the same time, rapid dispersion of the polyester-based material in the second mixed solution can be achieved. In addition, adding amino acids to dermal fillers can improve the cosmetic effect of dermal fillers as not only dispersants but also functional raw materials.

In a further embodiment, the polyester-based material is selected from one or more of poly-L-lactic acid, poly-D-lactic acid, polyglycolic acid, polyhydroxyalkanoate and polycaprolactone. The embodiment of the present application uses polyester material as the main component, which can not only prolong the degradation time of the dermal filler, but also effectively fill skin wrinkles and depressions.

In a further embodiment, the intrinsic viscosity of the polyester-based material is 0.2-5.0 dL/g. Therefore, by selecting a polyester-based material with an appropriate intrinsic viscosity, the degradation rate of the dermal filler can be effectively controlled, thereby improving the cosmetic effect of the dermal filler.

In a further embodiment, the particle size of the polyester material is 0.01-200 μm. Therefore, by selecting a polyester material with an appropriate particle size, not only can the depressions and wrinkles of the subcutaneous tissue be effectively filled, but also rapid pushing can be achieved during injection, avoiding difficulty in pushing.

In a further embodiment, the amino acid is selected from the group consisting of glycine, alanine, valine, leucine, isoleucine, proline, serine, phenylalanine, tryptophan and histidine one or more of. Thus, by adding the amino acid, not only can the mixed solution of the polyester-based material be effectively dispersed, but also the cosmetic effect of the dermal filler can be improved.

In a further embodiment, the intrinsic viscosity of the sodium hyaluronate is 0.5-4.0 m ³ /kg. Thus, by selecting the appropriate intrinsic viscosity of sodium hyaluronate, the expected degradation time of the dermal filler can be controlled.

The dermal fillers prepared in the examples of the present application can be used for filling and correcting wrinkles such as facial wrinkles, hand wrinkles, neck wrinkles, and stretch marks.

In a second aspect, the embodiments of the present application provide the preparation method of the dermal filler described in the first aspect of the embodiments of the present application. The method includes step 1: dissolving sodium hyaluronate and dispersant in water to prepare a first mixed solution; step 2: dissolving polyester materials in an organic solvent to prepare a second mixed solution; step 3: mixing The second mixed solution is quickly added to the first mixed solution, and fully emulsified to obtain an oil-in-water emulsion; step 4: desolventize the oil-in-water emulsion to obtain a suspension; step 5 : The suspension is lyophilized to obtain microparticles.

In the examples of the present application, a first mixed solution is obtained by dissolving sodium hyaluronate and a dispersant in water; a second mixed solution is obtained by dissolving the polyester material in an organic solvent; and then the second mixed solution is quickly added to the first mixed solution The emulsification treatment is carried out in the liquid, and the emulsified liquid after the emulsification treatment is desolvated to obtain a suspension. Compared with the existing technology for preparing microparticles, the process of removing the emulsifier and drying the microparticles is omitted, and the preparation of microparticles and the preparation of the dermal filler can be performed simultaneously, which simplifies the preparation process.

In a further embodiment, the organic solvent is one of ethyl acetate, chloroform, toluene and dichloromethane; thus, the polyester material can be effectively dissolved. In a further embodiment, the organic solvent is chloroform or dichloromethane. Thereby, the safety of the dermal filler can be improved.

In a further embodiment, in the step 3, the volume ratio of the first mixed solution and the second mixed solution is 1-20:1; in a further embodiment, the first mixed solution The volume ratio of the liquid to the second mixed liquid is 3 to 15:1; thus, a water-in-oil emulsion can be effectively obtained.

In a further embodiment, in the step 4, the temperature of the desolvation is 20-50°C.

It is also noted that, unless otherwise specified, any range recited in this application includes the endpoints and any values between the endpoints and any sub-ranges formed by the endpoints or any numbers between the endpoints.

Example 1

An injectable dermal filler, comprising the following raw materials by mass percentage: poly-L-lactic acid 35.6%, sodium hyaluronate 23.7%, mannitol 40.7%; the dermal filler is wrapped in poly-L-lactic acid by sodium hyaluronate and mannitol. particles formed on the surface of lactic acid.

The specific preparation method is as follows:

Step 1: dissolving sodium hyaluronate with an intrinsic viscosity of 0.9 m ³ /kg in water to prepare a sodium hyaluronate aqueous solution, wherein the mass percentage of sodium hyaluronate and water in the sodium hyaluronate aqueous solution is 1%. 10.3 g of mannitol was added to the sodium hyaluronate aqueous solution, and the mixture was stirred and dissolved to obtain a first mixed solution; wherein the first mixed solution was an aqueous phase.

Step 2: Weigh 9 g of poly-L-lactic acid with an intrinsic viscosity of 1.5 dL/g, dissolve it in 100 mL of dichloromethane, and prepare a second mixed solution; wherein the second mixed solution is an oil phase.

Step 3: Quickly add the second mixed solution to the first mixed solution, and use an emulsifier to emulsify for 3 minutes at a rotational speed of 2000 r/min to obtain an O/W emulsion.

Step 4: remove the solvent and part of the water from the emulsion at 30-50° C. to obtain a suspension; divide the suspension into multiple portions, place them in vials, and freeze-dry for 48 hours to obtain a dermal filler.

Reconstitution test: add 4 ml of water for injection to the prepared dermal filler, shake gently for 20 seconds to reconstitute to obtain a suspension; let the suspension stand for 10 minutes to remove air bubbles in the solution. From this, it can be seen that the reconstitution time of the dermal filler of the present embodiment is short.

Pushing force test: Use a 1 ml syringe to extract the suspension after standing, add a 30G needle, and use a microcomputer-controlled electronic universal testing machine to test the pushing force of the dermal filler. According to the test results, the average pushing force is 5N～10N. It can be seen from this that the dermal filler of this embodiment can achieve smooth pushing.

The particle size of the poly-L-lactic acid particles: After the suspension after standing is washed and dried, the morphology of the particles is observed with a scanning electron microscope, and the particle size of the particles is tested. As shown in Figure 1, the poly-L-lactic acid particles The particle size is 2 to 34 μm. It can be seen that the morphology and particle size of the poly-L-lactic acid particles of the present application are uniform, and it is not only suitable for deep dermis and subcutaneous tissue injection to fill deep wrinkles and depressions, but also suitable for superficial dermal water light injection to fill shallow wrinkles.

Example 2

An injectable dermal filler, comprising the following raw materials by mass percentage: poly-L-lactic acid 48.0%, sodium hyaluronate 20.0%, glycine 32.0%; the dermal filler is wrapped on the surface of poly-L-lactic acid by sodium hyaluronate and glycine particles formed.

The specific preparation method is as follows:

Step 1: dissolving sodium hyaluronate with an intrinsic viscosity of 2.1 m ³ /kg in water to prepare a sodium hyaluronate aqueous solution, wherein the mass percentage of sodium hyaluronate and water in the sodium hyaluronate aqueous solution is 0.5%. 4.0 g of glycine was added to the sodium hyaluronate aqueous solution, and the mixture was stirred and dissolved to obtain a first mixed solution; wherein the first mixed solution was an aqueous phase.

Step 2: Weigh 6 g of poly-L-lactic acid with an intrinsic viscosity of 1.8 dL/g, dissolve it in 80 mL of chloroform, and prepare a second mixed solution; wherein the second mixed solution is an oil phase.

Step 3: Quickly add the second mixed solution to the first mixed solution, and use an emulsifier to emulsify for 2 minutes at a rotational speed of 2500 r/min to obtain an O/W emulsion.

Step 4: remove the solvent and part of the water from the emulsion at 20-50° C. to obtain a suspension; divide the suspension into multiple portions, place them in vials, and freeze-dry for 48 hours to obtain a dermal filler.

Reconstitution test: add 4 ml of water for injection to the prepared dermal filler, shake gently for 25 seconds to reconstitute to obtain a suspension; let the suspension stand for 10 minutes to remove air bubbles in the solution. From this, it can be seen that the reconstitution time of the dermal filler of the present embodiment is short.

The particle size of the poly-L-lactic acid particles: After the suspension after standing is washed and dried, the morphology of the particles is observed with a scanning electron microscope, and the particle size of the particles is tested. As shown in Figure 2, the poly-L-lactic acid particles The particle size is 2 to 32 μm.

Example 3

An injectable skin filler, comprising the following raw materials by mass percentage: polycaprolactone 5.3%, sodium hyaluronate 3.4%, alanine 3.2% and water 88.1%; the skin filler is made of polycaprolactone in Suspension formed in sodium hyaluronate and alanine.

The specific preparation method is as follows:

Step 1: dissolving sodium hyaluronate with an intrinsic viscosity of 2.6 m ³ /kg in water to prepare a sodium hyaluronate aqueous solution, wherein the mass percentage of sodium hyaluronate and water in the sodium hyaluronate aqueous solution is 0.8%. 5.4 g of alanine was added to the sodium hyaluronate aqueous solution, and the mixture was stirred and dissolved to obtain a first mixed solution; wherein the first mixed solution was an aqueous phase.

Step 2: Weigh 9 g of polycaprolactone with an intrinsic viscosity of 1.6 dL/g, dissolve it in 90 mL of dichloromethane, and prepare a second mixed solution; wherein the second mixed solution is an oil phase.

Step 3: quickly add the second mixed solution to the first mixed solution, and emulsify for 3 min with an emulsifying machine at a rotational speed of 2500 r/min to obtain an O/W emulsion.

Step 4: remove the solvent and part of the water from the emulsion at 20-40°C to obtain a suspension; divide the suspension into multiple portions and fill them into prefilled syringes to obtain a dermal filler.

Pushing force test: add a 30G needle to the pre-filled syringe containing the suspension, and use a microcomputer-controlled electronic universal testing machine to test the pushing force of the dermal filler. According to the test results, the average pushing force is between 5N and 10N. . It can be seen from this that the dermal filler of this embodiment can achieve smooth pushing.

The particle size of the polycaprolactone particles: after the suspension after standing is washed and dried, the morphology of the particles is observed with a scanning electron microscope, and the particle size of the particles is tested, as shown in Figure 3. The particle diameter of the ester fine particles is 2 to 29 μm.

Example 4

An injectable skin filler, comprising the following raw materials by mass percentage: polylactic acid-polycaprolactone-polylactic acid 45.2%, sodium hyaluronate 21.7%, serine 33.1%; the skin filler is composed of sodium hyaluronate and Microparticles formed by wrapping serine on the surface of polylactic acid-polycaprolactone-polylactic acid.

The specific preparation method is as follows:

Step 1: dissolving sodium hyaluronate with an intrinsic viscosity of 3.0 m ³ /kg in water to prepare a sodium hyaluronate aqueous solution, wherein the mass percentage of sodium hyaluronate and water in the sodium hyaluronate aqueous solution is 0.4%. 5.5 g of serine was added to the sodium hyaluronate aqueous solution, and the mixture was stirred and dissolved to obtain a first mixed solution; wherein the first mixed solution was an aqueous phase.

Step 2: Weigh 7.5 g of polylactic acid-polycaprolactone-polylactic acid with an intrinsic viscosity of 1.3dL/g, dissolve it in 80 mL of dichloromethane, and prepare a second mixed solution; wherein the second mixed solution is an oil phase. .

Step 3: Quickly add the second mixed solution to the first mixed solution, and use an emulsifying machine to emulsify for 2.5 minutes at a rotational speed of 2400 r/min to obtain an O/W emulsion.

Step 4: remove the solvent and part of the water from the emulsion at 20-40° C. to obtain a suspension; divide the suspension into multiple portions, place them in vials, freeze-dry for 48 hours, and obtain a dermal filler.

Reconstitution test: add water for injection to the prepared dermal filler, shake gently for 35 seconds to reconstitute to obtain a suspension; let the suspension stand for 10 minutes to remove air bubbles in the solution. From this, it can be seen that the reconstitution time of the dermal filler of the present embodiment is short.

Particle size of polylactic acid-polycaprolactone-polylactic acid particles: After the suspension after standing is washed and dried with water, the morphology of the particles is observed with a scanning electron microscope, and the particle size of the particles is tested, as shown in Figure 4 As shown, the particle size of the polylactic acid-polycaprolactone-polylactic acid microparticles is 2 to 34 μm.

Example 5

An injectable skin filler, comprising the following raw materials by mass percentage: poly-L-lactic acid-glycolic acid 36.6%, sodium hyaluronate 16.3%, mannitol 47.1%; the skin filler is composed of sodium hyaluronate and mannitol Microparticles formed on the surface of poly-L-lactic-glycolic acid.

The specific preparation method is as follows:

Step 1: dissolving sodium hyaluronate with an intrinsic viscosity of 3.4 m ³ /kg in water to prepare a sodium hyaluronate aqueous solution, wherein the mass percentage of sodium hyaluronate and water in the sodium hyaluronate aqueous solution is 0.4%. 11.6 g of mannitol was added to the aqueous sodium hyaluronate solution, and stirred to dissolve to obtain a first mixed solution; wherein the first mixed solution was an aqueous phase.

Step 2: Weigh 9 g of poly-L-lactic acid-glycolic acid with an intrinsic viscosity of 1.9 dL/g, dissolve it in 80 mL of chloroform, and prepare a second mixed solution; wherein the second mixed solution is an oil phase.

Step 3: Quickly add the second mixed solution to the first mixed solution, and use an emulsifier to emulsify for 2 minutes at a rotational speed of 2800 r/min to obtain an O/W emulsion.

Reconstitution test: add water for injection to the prepared dermal filler, shake gently for 40 seconds to reconstitute to obtain a suspension; let the suspension stand for 10 minutes to remove air bubbles in the solution. From this, it can be seen that the reconstitution time of the dermal filler of the present embodiment is short.

Particle size of poly-L-lactic acid-glycolic acid particles: After the suspension after standing is washed and dried with water, the morphology of the particles is observed with a scanning electron microscope, and the particle size of the particles is tested, as shown in Figure 5, The particle size of the poly-L-lactic-glycolic acid fine particles is 2 to 34 μm.

Example 6

An injectable skin filler, comprising the following raw materials by mass percentage: polycaprolactone 37.0%, sodium hyaluronate 11.5%, and mannitol 51.5%; the skin filler is wrapped in polycaprolactone by sodium hyaluronate and mannitol. Microparticles formed on the surface of lactones.

The specific preparation method is as follows:

Step 1: dissolving sodium hyaluronate with an intrinsic viscosity of 3.8 m ³ /kg in water to prepare a sodium hyaluronate aqueous solution, wherein the mass percentage of sodium hyaluronate and water in the sodium hyaluronate aqueous solution is 0.3%. 12.1 g of mannitol was added to the sodium hyaluronate aqueous solution, and stirred and dissolved to obtain a first mixed solution; wherein the first mixed solution was an aqueous phase.

Step 2: Weigh 8.7 g of polycaprolactone with an intrinsic viscosity of 1.2 dL/g, dissolve it in 90 mL of dichloromethane, and prepare a second mixed solution; wherein the second mixed solution is an oil phase.

Step 3: Quickly add the second mixed solution to the first mixed solution, and emulsify for 3 min with an emulsifying machine at a rotational speed of 2300 r/min to obtain an O/W emulsion.

Reconstitution test: add water for injection to the prepared dermal filler, shake gently for 45 seconds to reconstitute to obtain a suspension; let the suspension stand for 10 minutes to remove air bubbles in the solution. From this, it can be seen that the reconstitution time of the dermal filler of the present embodiment is short.

The particle size of the polycaprolactone particles: After the suspension after standing is washed and dried with water, the morphology of the particles is observed with a scanning electron microscope, and the particle size of the particles is tested, as shown in Figure 6. The particle diameter of the ester fine particles is 2 to 36 μm.

In the description of this specification, the particular features, structures, materials or characteristics described may be combined in any suitable manner in any one or more embodiments or examples. Furthermore, those skilled in the art may combine and combine the different embodiments or examples described in this specification, as well as the features of the different embodiments or examples, without conflicting each other.

In addition, the terms "first" and "second" are only used for descriptive purposes, and should not be construed as indicating or implying relative importance or implying the number of indicated technical features. Thus, a feature delimited with "first", "second" may expressly or implicitly include at least one of that feature. In the description of the present application, "plurality" means two or more, unless otherwise expressly and specifically defined.

The above are only specific embodiments of the present application, but the protection scope of the present application is not limited to this. should be covered within the scope of protection of this application. Therefore, the protection scope of the present application should be subject to the protection scope of the claims.

Claims

An injectable dermal filler is characterized in that it comprises the following raw materials by mass percentage: polyester material, sodium hyaluronate, and dispersant.
The dermal filler according to claim 1, wherein the dermal filler comprises 20%-80% of the polyester material, 10%-40% of sodium hyaluronate, and 10%-60% of the dispersant; It is a particle formed by coating the surface of polyester material with sodium hyaluronate and dispersant.
The dermal filler according to claim 1, further comprising water; 5% to 20% of polyester microparticles, 1% to 5% of sodium hyaluronate, 2% to 10% of dispersant and 65% of water ~90%; the dermal filler is a suspension formed by polyester microparticles in sodium hyaluronate and a dispersant.
The dermal filler according to claim 1, wherein the dispersing agent is mannitol and amino acid; preferably, the mass percentage of the amino acid in the dermal filler is 2% to 50%, and the mannitol The mass percentage of alcohol in the dermal filler is 2% to 50%.
The dermal filler according to claim 1, wherein the polyester material is selected from the group consisting of polycaprolactone, poly-L-lactic acid, poly-D-lactic acid, polyglycolic acid and polyhydroxyalkanoate or more; preferably, the intrinsic viscosity of the polyester material is 0.2-5.0 dL/g; more preferably, the particle size of the polyester material is 0.01-200 μm.
The dermal filler according to claim 4, wherein the amino acid is selected from the group consisting of glycine, alanine, valine, leucine, isoleucine, proline, serine, phenylalanine, One or more of tryptophan and histidine.
The dermal filler according to claim 1, wherein the intrinsic viscosity of the sodium hyaluronate is 0.5-4.0 m 3 /kg.
A preparation method of the dermal filler as described in any one of claims 1 to 7, characterized in that, comprising the steps:

Step 1: Dissolve sodium hyaluronate and dispersant in water to prepare a first mixed solution;

Step 2: dissolving the polyester material in an organic solvent to prepare a second mixed solution;

Step 3: the second mixed solution is quickly added to the first mixed solution, and fully emulsified to obtain an oil-in-water emulsion;

Step 4: desolventizing the oil-in-water emulsion to obtain a suspension;

Step 5: freeze-drying the suspension to obtain a microparticle-containing dermal filler.
The method according to claim 8, wherein the organic solvent is one of ethyl acetate, chloroform, toluene and dichloromethane; preferably, the organic solvent is dichloromethane or trichloromethane Methane.
The method according to claim 8, wherein in the step 3, the volume ratio of the first mixed solution and the second mixed solution is 1-20:1; preferably, in the step In the fourth step, the temperature of the desolvation is 20-50°C.